Cure­Vac walks away from Arc­turus' urea cy­cle dis­or­der drug, but part­ner­ship re­mains in­tact

Arc­turus Ther­a­peu­tics had a melo­dra­mat­ic 2018 — the San Diego biotech’s CEO Joseph Payne was asked to leave for putting his in­ter­ests be­fore the RNA com­pa­ny, but he fought back with the sup­port of share­hold­ers, oust­ed the board that spear­head­ed his ouster and was re­in­stat­ed. But un­der Payne, the drug de­vel­op­er has lost the sup­port of col­lab­o­ra­tor Cure­Vac in the de­vel­op­ment of a drug for the most com­mon urea cy­cle dis­or­der — or­nithine tran­scar­bamy­lase de­fi­cien­cy (OTCD), a life-threat­en­ing ge­net­ic dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER